FRI0096 Predictive Value of The Multi-Biomarker Disease Activity (MBDA) Score for Flare and Sustained Remission in The Honor Study

Objectives To determine the predictive value of the multi-biomarker disease activity (MBDA) (Vectra® DA) score for flare and sustained clinical remission after discontinuation of adalimumab (ADA) in patients with rheumatoid arthritis (RA) from the HONOR study [1,2]. Methods This retrospective sub-analysis was conducted on 42 RA patients from the HONOR study. Patients receiving ADA and methotrexate (MTX) who maintained DAS28-ESR remission ( 44) were determined from serum samples collected at baseline. The ability to predict flare (DAS28-ESR ≥3.2) or sustained clinical remission (SC-REM) (absence of flare with DAS28-ESR Results At ADA discontinuation, all patients had DAS28-ESR Conclusions These findings suggest that the MBDA score could predict flare and SC-REM in RA patients in stable clinical remission, undergoing ADA withdrawal while maintaining MTX treatment. References Hirata S, et al, Arthritis Res Ther. 2013;15:R135 Tanaka Y, et al, Ann Rheum Dis. 2015;74:389–395 Disclosure of Interest S. Hirata Speakers bureau: AbbVie, Eisai, Bristol Meyers Squibb, S. Tang Employee of: Crescendo Bioscience Inc., C. Hwang Employee of: Crescendo Bioscience Inc., I. Miyagawa: None declared, S. Kubo: None declared, K. Nakano: None declared, S. Nakayamada: None declared, K. Saito: None declared, N. Defranoux Employee of: Crescendo Bioscience Inc., Y. Tanaka Grant/research support from: Mitsubishi-Tanabe, Chugai, MSD, Astellas, Novartis, Speakers bureau: Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB, GlaxoSmithKline, Bristol-Myers